Pharmaceutical Regulation in Kenya: Product Registration and Compliance

Pharmaceutical regulation in Kenya is anchored by the Pharmacy and Poisons Board (PPB), which operates under the Pharmacy and Poisons Act (Cap 244). The Board registers pharmaceutical products, licenses manufacturers, wholesalers and pharmacies, authorises clinical trials and controls importation and distribution. For any business bringing a medicine, vaccine, herbal remedy or other health product to the Kenyan market, understanding how the PPB exercises this authority is the difference between a smooth launch and a registration refusal, a seizure or a prosecution.

The Legal Basis for Pharmaceutical Regulation in Kenya

Section 3A of the Act empowers the Board to formulate guidelines for regulating medical products, grant or withdraw authorisation for clinical trials, grant or withdraw marketing authorisation, recall products from the market, grant or withdraw licences to manufacturers, wholesalers, retailers, importers, exporters and distributors, and prescribe standards for new medical products. Day-to-day registration decisions now sit under the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 (Legal Notice 100 of 2022), published in the Kenya Gazette on 17 June 2022.

Registering a Health Product or Technology

Under rule 4 of the 2022 Rules, a person who intends to import, manufacture or sell a health product or technology must apply to the Board for its registration in Form 1 in the First Schedule. The application must be accompanied by, among other things, a proposed label, the manufacturing licence where applicable, a good manufacturing practice certificate, a certificate of analysis from a quality control laboratory recognised by the Board, the marketing authorisation or certificate of registration from the regulator of the country where the product is sold, data on quality, safety, efficacy and performance in a common technical dossier format, and a sample of the product. The Board’s Compendium of Guidelines on Medicines Evaluation and Registration sets out how it expects dossiers to be prepared.

Registration is not a one-time event. The holder remains responsible for labelling, packaging, advertising and post-market safety monitoring for as long as the product stays on the Kenyan market, and the 2022 Rules also provide for variation of the information on a registered product.

Foreign Manufacturers and Local Representatives

Where the applicant is not a Kenyan citizen or is a company incorporated outside Kenya, rule 4(2)(b) requires the appointment of a local representative, who must be a Kenyan citizen, a person with permanent residence, or a company incorporated in Kenya. A copy of the agreement appointing that representative must accompany the application. For a foreign pharmaceutical or medical technology company, getting this relationship right at the outset, with clear contractual responsibility for safety reporting, recall coordination and regulatory correspondence, is one of the more commonly underestimated steps in market entry.

Manufacturing, Wholesale and Premises Licensing

Separately from product registration, anyone manufacturing, wholesaling, importing or operating pharmacy premises needs the relevant PPB licence for that activity. Section 23 of the Act requires premises from which the business of a pharmacist is carried on to be registered, and a contravention is punishable by a fine of up to KES 1,000,000 or imprisonment of up to three years, or both. Under the Act’s licensing provisions, the Board may refuse to issue or renew, or may revoke, a licence for good and sufficient reason, with an appeal to the Cabinet Secretary whose decision is final. Rule 4(3)(k) of the 2022 Rules also requires a product applicant to prove that it holds the licences relevant to its activities, including a wholesale dealer’s licence under section 27 of the Act.

Importation, Clinical Trials and Pharmacovigilance

Importing health products is a distinct compliance workstream from registration. The Board licenses importers and exporters under section 3A, and an unregistered product or an unlicensed importer can hold a shipment at the border regardless of the other being in order. Treat the two applications as parallel tracks on different timelines, a point that sits at the centre of pharmaceutical regulation in Kenya.

The Board may also grant or withdraw authorisation for clinical trials, and a dossier that relies on locally generated clinical data will be scrutinised accordingly. After launch, the Act defines post-market surveillance as monitoring the safety and quality of a product after release, and the Board can recall products or withdraw marketing authorisation where safety concerns emerge.

Advertising and Promotion Restrictions

Section 36 of the Act prohibits advertising any drug or poison without the Board’s written permission. Section 37 prohibits advertisements implying a drug may be effective for the purposes listed in the Schedule to the Act, section 38 prohibits advertisements calculated to lead to the use of drugs for abortion, and section 39 prohibits advertisements that the Board considers extravagant and bearing little or no relation to the pharmacological properties of the product. Under section 40, a first conviction for breaching sections 36 to 39 carries a fine of up to KES 20,000 or imprisonment for up to one year, or both, and a subsequent conviction a fine of up to KES 30,000 or imprisonment for up to two years, or both. Marketing teams should treat PPB advertising clearance as a standing item in their promotional review process.

Enforcement Powers and Penalties

Offences under the Act for which no other penalty is provided attract, under section 51, a fine of up to KES 1,000,000 or imprisonment for up to two years, or both, and the court may order forfeiture of the articles involved. Practising as a pharmacist without registration carries a fine of up to KES 30,000 or imprisonment for up to three years, or both. Penalties therefore vary widely by provision, and each activity needs to be checked against the specific section that governs it.

Practical Compliance Guidance

For a first-time entrant in pharmaceutical regulation in Kenya, the realistic sequence rarely runs “register, then sell”. It runs in parallel: securing the local representative, reviewing the dossier against the 2022 Rules and the Compendium, lining up import licensing alongside registration, and building advertising and labelling review into the launch timeline before commercial materials are finalised.